Periochip

Shelf life

2.5 years.

Incompatibilities

Nystatin is known to be antagonistic to the efficacy of chlorhexidine.

List of excipients

Hydrolysed gelatin (cross-linked with glutaraldehyde) Glycerol

Purified water

Preclinical safety data

Periochip has been tested for cytotoxicity in vitro, for mutagenicity using the mouse micronucleus assay, for oral mucosal irritation potential using a Hamster cheek pouch model and for subchronic oral toxicity in a 30 day ingestion study in rats.

Cytotoxicity

In Chinese Hamster lung cells (V79), Periochip showed marked in vitro cytotoxicity. The cytotoxicity of the Periochip was considerably less than that of chlorhexidine digluconate alone and was reduced by the addition of a rat liver-derived, metabolic activation system. Thus, the cytotoxicity of the active, chlorhexidine digluconate, is reduced when incorporated into the Periochip

Mutagenicity

The potential of Periochip to induce chromosomal or other damage was assessed in vivo by evaluating the formation of micronuclei in immature bone marrow erythrocytes in mice. No significant chromosomal or other damage was observed with the Periochip for any test dose up to and including 1240 mg/kg chlorhexidine digluconate compared to the vehicle control.

Oral mucosal irritation

The potential of Periochip to induce irritation was evaluated through surgical insertion into Hamster cheek pouches for either 7 or 14 days. Mucosal irritation was observed after removal of the Periochips and, through comparison with sites treated with placebo dental inserts, was considered to be caused by the chlorhexidine digluconate. There were few instances of significant differences in erythema and oedema. The effects were transitory and the animals had recovered seven days after dental insert removal, indicating either that the initial localised effects were biologically insignificant or that the healing process was rapid.

Oral toxicity

Daily dosing for 30 days with up to 37.5 mg/kg of Periochip powder containing chlorhexidine digluconate caused no adverse reactions in rats.

Pharmacotherapeutic group

Stomatological preparations; Antiinfectives and antiseptics for local oral treatment.

Date of revision of the text

11/2014

Marketing authorisation holder

Dexcel-Pharma Limited

7 Sopwith Way, Drayton Fields

Daventry

Northamptonshire

NN11 8PB

United Kingdom

Special precautions for storage

Do not store above 30°C.

Nature and contents of container

Blister (laminated aluminium foil blister packs), each containing 2, 10 or 20 dental inserts.

Marketing authorisation number(s)

PL 14017/0035

Special precautions for disposal and other handling

No special requirements.

Date of first authorisation/renewal of the authorisation

14 November 2006